Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca PLC    AZN   GB0009895292


SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

FTSE 100 closes lower on weak oil majors; Midcaps boosted by G4S

09/14/2020 | 04:39am EST

* No-deal Brexit fears cap gains

* All eyes on BoE meeting on Thursday

* BP drops after it forecasts weak crude demand

* Security firm G4S marks best day ever

Sept 14 (Reuters) - London's blue-chip index fell on Monday as the prospect of waning demand weighed on heavyweight energy stocks, while security firm G4S propped up the midcap index after it rejected a takeover from Canadia's GardaWorld.

The blue-chip FTSE 100 shed 0.1%, with oil and gas major BP weighing the most after it forecast declining fossil fuel demand due to climate policies and the coronavirus epidemic. Oil prices were steady.

The mid-cap index added 0.7%, with G4S surging to a near seven-month high after it rejected a 2.95 billion pound ($3.8 billion) offer from Canadian security firm GardaWorld, saying it was "highly opportunistic".

Divorce talks between the United Kingdom and the European Union continued to be at the forefront, with the bloc ramping up pressure on Prime Minister Boris Johnson to step back from breaking the Brexit divorce treaty.

"Brexit is back with a bang, and there’s a growing risk that the transition period will end with no trade agreement in place between the UK and the EU," ING economists wrote in a note.

Markets are also awaiting Thursday's Bank of England policy meeting, where it is likely to signal more stimulus to lift the economy out of a deep recession that could be exacerbated by a messy Brexit.

While steady stimulus has helped the FTSE 100 bounce from its coronavirus lows earlier this year, surging cases and middling economic data have seen the index stall in recent months, with new Brexit fears also expected to weigh in the near-term.

Drugmaker AstraZeneca fell slightly, despite resuming British clinical trials of its COVID-19 vaccine, which is one of the most advanced in development.

British recruiting firm SThree Plc rose 1.4% as it said its underlying sequential performance had been improving since the first half of the year. (Reporting by Shashank Nayar in Bengaluru; Editing by Subhranshu Sahu and Steve Orlofsky)

© Reuters 2020
Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC -0.86% 7651 Delayed Quote.4.38%
BP PLC 0.27% 302.05 Delayed Quote.18.86%
EURO / BRITISH POUND (EUR/GBP) 0.01% 0.8864 Delayed Quote.-0.41%
G4S PLC 0.54% 259.6 Delayed Quote.2.29%
LONDON BRENT OIL 0.34% 55.86 Delayed Quote.5.90%
MSCI UNITED KINGDOM (STRD, UHD) 0.47% 1074.11 Real-time Quote.3.69%
STHREE PLC 0.76% 330.5 Delayed Quote.10.91%
WTI 0.23% 53.064 Delayed Quote.8.53%
All news about ASTRAZENECA PLC
01/20Oxford University Works On New Vaccine Versions Against COVID-19 Strains
01/20World Health Organization Nears Emergency Approval for Three COVID-19 Vaccine..
01/20McKesson to replace some Moderna COVID-19 vaccines due to low temperature
01/20Oxford scientists preparing vaccine versions to combat emerging virus variant..
01/20WHO plans slew of COVID-19 vaccine approvals for global rollout
01/20Three COVID-19 vaccines under final review for emergency use - WHO
01/20Glass maker Schott predicts enough vials to go around for COVID-19 vaccines
01/20WHO plans slew of COVID-19 vaccine approvals for global rollout - document
01/20ASTRAZENECA : India, 'pharmacy of the world', starts COVID vaccine shipments to ..
01/20ASTRAZENECA : Receives a Buy rating from Credit Suisse
More news
Financials (USD)
Sales 2020 26 394 M - -
Net income 2020 2 985 M - -
Net Debt 2020 13 227 M - -
P/E ratio 2020 41,2x
Yield 2020 2,69%
Capitalization 137 B 137 B -
EV / Sales 2020 5,70x
EV / Sales 2021 4,94x
Nbr of Employees 70 600
Free-Float 95,7%
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | AZN | GB0009895292 | MarketScreener
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 25
Average target price 125,97 $
Last Close Price 104,48 $
Spread / Highest target 49,4%
Spread / Average Target 20,6%
Spread / Lowest Target -19,5%
EPS Revisions
Managers and Directors
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Menelas N. Pangalos EVP-Biopharmaceuticals Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON3.18%428 525
ROCHE HOLDING AG2.98%307 190
NOVARTIS AG2.24%218 823
MERCK & CO., INC.1.70%210 474
PFIZER INC.-0.84%204 160